Clinical Specialty Portfolio

DIABETOLOGY & METABOLIC CARE

2 Formulations

Evidence-based oral anti-diabetic therapeutics formulated for synchronized fasting and post-prandial glycemic control.

Clinical Focus

Type-2 Diabetes Mellitus, Glycemic Modulation & Insulin Sensitivity

Key Molecules:GlimepirideMetformin HCl SRVoglibosePioglitazone

Marketed Formulations in Diabetology & Metabolic Care

Each product is formulated in compliance with strict Indian Pharmacopoeia assay standards.

Bilayered Tablets

Schedule H Rx

Glimepiride, Metformin HCl (SR) & Voglibose Tablets

Triple-combination anti-diabetic tablet for synchronized fasting and post-prandial glucose control in Type 2 Diabetes.

Composition: Glimepiride 2 mg, Metformin Hydrochloride (SR) 500 mg, Voglibose 0.2 mg, Excipients q.s.

Pack: Strip of 10 Tablets

Film-coated Tablets

Schedule H Rx

Glimepiride, Pioglitazone & Metformin HCl (SR) Tablets

Triple-action anti-diabetic formulation targeting peripheral insulin resistance and sustained glycemic control.

Composition: Glimepiride 2 mg, Pioglitazone Hydrochloride 15 mg, Metformin Hydrochloride (SR) 500 mg, Excipients q.s.

Pack: Strip of 10 Tablets